Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 9/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29987037 | 1.00 | ALDH1A1 (0.49) | ALDH1A1NPSR1MEN1RECQLKMT2A | |
| SCHEMBL288384 | 1.00 | ALDH1A1 (0.49) | ALDH1A1NPSR1MEN1RECQLKMT2A | |
| SCHEMBL29986539 | 1.00 | ALDH1A1 (0.49) | ALDH1A1NPSR1MEN1RECQLKMT2A | |
| SCHEMBL1468174 | 1.00 | ALDH1A1 (0.49) | ALDH1A1NPSR1MEN1RECQLKMT2A | |
| SCHEMBL5980144 | 1.00 | ALDH1A1 (0.49) | ALDH1A1NPSR1MEN1RECQLKMT2A | |
| SCHEMBL38558 | 1.00 | ALDH1A1 (0.49) | ALDH1A1NPSR1MEN1RECQLKMT2A | |
| SCHEMBL38557 | 1.00 | ALDH1A1 (0.49) | ALDH1A1NPSR1MEN1RECQLKMT2A | |
| SCHEMBL1468176 | 1.00 | ALDH1A1 (0.49) | ALDH1A1NPSR1MEN1RECQLKMT2A | |
| SCHEMBL16635360 | 1.00 | ALDH1A1 (0.49) | ALDH1A1NPSR1MEN1RECQLKMT2A | |
| SCHEMBL6440341 | 1.00 | ALDH1A1 (0.49) | ALDH1A1NPSR1MEN1RECQLKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022215745-A1 | SUBSTANCE OF NOVEL SIDEROPHORE-TYPE ANTIFUNGAL AGENT (COMPOUND) AND USE OF SAME | 国立研究開発法人理化学研究所 | 2022-10-13 | — | — | WO | disclosed |
| EP-1505062-A1 | Heterocyclic derivatives and their use as antithrombotic agents | Akzo Nobel N.V. (NL) | 2005-02-09 | — | — | EP | disclosed |
| US-6797710-B2 | CARDIOVASCULAR DISORDERS; SERINE PROTEASE INHIBITOR; ADMINISTERING BY MOUTH; BIOAVAILABILITY | AKZO NOBEL N.V. (NL) | 2004-09-28 | — | — | US | disclosed |
| EP-1012164-B1 | SERINE PROTEASE INHIBITORS | AKZO NOBEL NV (NL) | 2004-09-22 | — | — | EP | disclosed |
| EP-0979240-B1 | SERINE PROTEASE INHIBITORS | AKZO NOBEL NV (NL) | 2004-04-14 | — | — | EP | disclosed |
| US-20030130270-A1 | Heterocyclic derivatives and their use as antithrombotic agents | MERCK SHARP & DOHME B.V. (NL) | 2003-07-10 | — | — | US | disclosed |
| EP-0858464-B1 | THROMBIN INHIBITORS | AKZO NOBEL NV (NL) | 2003-05-07 | — | — | EP | disclosed |
| US-6534495-B1 | Anticoagulants that prevent thrombin-related diseases. | AKZO NEBEL (NL) | 2003-03-18 | — | — | US | disclosed |
| US-20020142967-A1 | Thrombin inhibitors | ADANG A E P (NL) | 2002-10-03 | — | — | US | disclosed |
| US-6444672-B1 | ORAL BIOVAILABILITY; INHIBITORS OF THROMBIN AND/OR FACTOR XA; SERINE PROTEASE INHIBITOR | AKZO NOBEL N.V. (NL) | 2002-09-03 | — | — | US | disclosed |
| WO-1998050420-A1 | SERINE PROTEASE INHIBITORS | AKZO NOBEL N.V. (NL) | 1998-11-12 | — | — | WO | disclosed |
| WO-1998047876-A1 | HETEROCYCLIC DERIVATIVES AND THEIR USE AS ANTITHROMBOTIC AGENTS | AKZO NOBEL N.V. (NL) | 1998-10-29 | — | — | WO | disclosed |
| EP-0858464-A1 | THROMBIN INHIBITORS | Akzo Nobel N.V. (NL) | 1998-08-19 | — | — | EP | disclosed |
| EP-0830371-A1 | IMIDAZO 1,5a]PYRIDINE DERIVED SERINE PROTEASE INHIBITORS | Akzo Nobel N.V. (NL) | 1998-03-25 | — | — | EP | disclosed |
| WO-1997031937-A1 | SERINE PROTEASE INHIBITORS | AKZO NOBEL N.V. (NL) | 1997-09-04 | — | — | WO | disclosed |
| WO-1997031939-A1 | SERINE PROTEASE INHIBITORS | AKZO NOBEL N.V. (NL) | 1997-09-04 | — | — | WO | disclosed |
| WO-1997030073-A1 | SERINE PROTEASE INHIBITORS | AKZO NOBEL N.V. (NL) | 1997-08-21 | — | — | WO | disclosed |
| WO-1997017363-A1 | THROMBIN INHIBITORS | AKZO NOBEL N.V. (NL) | 1997-05-15 | — | — | WO | disclosed |
| WO-1996038470-A1 | IMIDAZO[1,5a]PYRIDINE DERIVED SERINE PROTEASE INHIBITORS | AKZO NOBEL N.V. (NL) | 1996-12-05 | — | — | WO | disclosed |
| US-5128448-A | Peptide hormones | HOFFMAN-LA ROCHE INC. (US) | 1992-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020142967-A1 | Thrombin inhibitors | SERPINC1, DAO, CTRL | ALDH1A1 2677/4885NPSR1 1829/4885MEN1 4623/4885 |
| US-20030130270-A1 | Heterocyclic derivatives and their use as antithrombotic agents | F2, F12, VKORC1 | ALDH1A1 170/4885NPSR1 457/4885MEN1 1002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.